Bayhill Therapeutics, Inc. Doses Patients With Multiple Sclerosis In A Phase II Trial And Raises An Additional $15.8 Million As An Extension To Its Series B Financing
Summary
Bayhill Therapeutics dosed patients in a Phase II trial for multiple sclerosis with its BHT-3009 candidate. The company also raised an additional $15.8 million as an extension to its Series B financing. Current investors provided the new capital to help advance BHT-3021 into human clinical trials for Type 1 diabetes. Bayhill also added David Thompson, a longtime Eli Lilly business development executive, to its board to support partnering efforts.
Funding
Amount
$15.8M
Total raised
Date
April 10, 2006
Announcement date
Investors
U.S. Venture Partners, Montreux Equity Partners, Morgenthaler Ventures, Vertical Group, Lilly Ventures, CMEA Ventures
Lead investors
Company
http://bayhilltx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected